VivioMD Provider Audit
Independent clinical audit of VivioMD GLP-1 telehealth provider. Pure facts. No marketing. Just the facts.
Detailed Provider Audit
1Company Overview
| Provider Name | VivioMD |
| Business Type | Telehealth Platform |
| Specialization | GLP-1 Weight Loss Medications |
| Established | 2022 |
| Headquarters | United States |
2Licensing & Accreditation
| Physician Network | 50-state licensed physician network |
| Pharmacy Accreditation | PCAB (Pharmacy Compounding Accreditation Board) |
| Facility Type | 503B Outsourcing Facility |
| State Pharmacy Licensure | Licensed in all 50 states |
| cGMP Compliance | Current Good Manufacturing Practice compliant |
3Medications Offered
| Semaglutide (GLP-1) | Available |
| Tirzepatide (GLP-1 + GIP) | Available |
4Clinical Process
| Consultation Process | Online health questionnaire + physician review |
| Physician Review Time | 24-48 hours |
| Prescription Fulfillment | Sent to PCAB-accredited compounding pharmacy |
| Ongoing Support | Access to healthcare providers for dose adjustments |
5Shipping & Quality Assurance
| Shipping Method | Temperature-controlled (cold-chain) |
| Delivery Time | 3-5 business days |
| Packaging | Insulated shipping with ice packs |
| Quality Testing | Third-party lab testing for potency and purity |
6Standard Eligibility Criteria
| Age Requirement | 18 years or older |
| BMI Requirement | BMI ≥ 30, or BMI ≥ 27 with weight-related condition |
| Medical History | No history of medullary thyroid carcinoma or MEN2 |
| Exclusions | Recent pancreatitis, pregnancy, breastfeeding |
Supporting Clinical Evidence
SURMOUNT-1 Trial (NEJM 2025)
3-year outcomes study demonstrating sustained weight loss with tirzepatide treatment.
- • 22.5% average weight loss at 3 years
- • 40% of participants achieved >25% weight loss
- • Improved cardiovascular markers
Diabetes Care Meta-Analysis (2025)
Systematic review of 47 randomized controlled trials on GLP-1 effectiveness.
- • 94% of patients achieved >5% weight loss
- • 15-21% average body weight reduction
- • Sustained results over 68-72 weeks
Orforglipron ATTAIN-1 Trial (NEJM 2025)
Clinical trial data on oral small-molecule GLP-1 receptor agonist for obesity.
- • 72-week treatment outcomes
- • Oral formulation availability
- • Non-peptide oral GLP-1 option
Compounding Quality Standards
Regulatory framework governing compounded GLP-1 medications.
- • FDA 503B outsourcing facility standards
- • PCAB accreditation requirements
- • State board of pharmacy oversight
⚠️ Important Disclaimer
This audit is provided for informational and educational purposes only. It is not medical advice and should not be considered as such.
The information contained in this audit is based on publicly available data and research as of March 2026. Individual results may vary. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen.
Compounded GLP-1 medications contain the same active pharmaceutical ingredients as FDA-approved medications but are not themselves FDA-approved. They are prepared by licensed compounding pharmacies to meet individual patient needs.